Journal
CANCER AND METASTASIS REVIEWS
Volume 31, Issue 1-2, Pages 375-386Publisher
SPRINGER
DOI: 10.1007/s10555-012-9348-x
Keywords
Hakai; E3 ubiquitin-ligase; E-cadherin; Epithelial-mesenchymal transition
Categories
Funding
- Secretaria Xeral I + D + I, Xunta de Galicia, Spain [IPP.08-07, 10CSA916023PR]
- Conselleria de Sanidade, Xunta de Galicia, Spain [PS09/24]
Ask authors/readers for more resources
In order to metastasize, cancer cells must first detach from the primary tumor, migrate, invade through tissues, and attach to a second site. Hakai was discovered as an E3 ubiquitin-ligase that mediates the posttranslational downregulation of E-cadherin, a major component of adherens junctions in epithelial cells that is characterized as a potent tumor suppressor and is modulated during various processes including epithelial-mesenchymal transition. Recent data have provided evidences for novel biological functional role of Hakai during tumor progression and other diseases. Here, we will review the knowledge that has been accumulated since Hakai discovery 10 years ago and its implication in human cancer disease. We will highlight the different signaling pathways leading to the influence on Hakai and suggest its potential usefulness as therapeutic target for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available